Susan O'Brien
苏珊·奥布莱恩
MD
Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center肿瘤中心临床科学副主任
👥Biography 个人简介
Dr. Susan O'Brien is a globally recognized CLL expert who played a pivotal role in establishing ibrutinib as a frontline standard of care. She led the landmark RESONATE trial, transforming outcomes for relapsed/refractory CLL patients worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Ibrutinib in CLL
Led and co-led key ibrutinib trials including RESONATE and RESONATE-2, establishing BTK inhibition as the standard of care for both frontline and relapsed/refractory CLL, dramatically improving progression-free survival.
BTK Inhibitor Development
Contributed extensively to early-phase BTK inhibitor studies defining optimal dosing, tolerability, and long-term efficacy data that supported FDA approval of ibrutinib across multiple CLL indications.
Representative Works 代表性著作
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia (RESONATE-2)
New England Journal of Medicine (2015)
Phase 3 trial establishing ibrutinib superiority over chlorambucil in frontline CLL, leading to FDA approval.
Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory CLL
Blood (2018)
Long-term follow-up confirming durable responses and favorable safety profile of ibrutinib in CLL.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 苏珊·奥布莱恩 的研究动态
Follow Susan O'Brien's research updates
留下邮箱，当我们发布与 Susan O'Brien（University of California Irvine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment